Abstract
The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and cytokinesis. The role of aurora C is less clear. Overexpression of aurora A and B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. Several small molecules targeting aurora kinases A and B or both have been evaluated preclinically and in early phase I trials. In this review we aim to summarize the most recent advances in the development of aurora kinase inhibitors, with a focus on the clinical data. The Oncologist 2009; 14: 780-793
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 780-793 |
| Number of pages | 14 |
| Journal | Oncologist |
| Volume | 14 |
| Issue number | 8 |
| Publication status | Published - 2009 |
